Keyphrases
Dosimetry
100%
PET Imaging
100%
First-in-human Study
100%
Soluble Urokinase Plasminogen Activator Receptor (suPAR)
100%
Detection Efficiency
100%
Radioligand
100%
Gallium-68
100%
AE105
100%
Prostate Cancer
83%
Tumor-like Lesions
50%
Urinary Bladder Cancer
50%
First-in-human
33%
After Injection
33%
Phase I Clinical Trial
33%
Biodistribution
33%
Breast Cancer
33%
In Vivo Stability
33%
Total-body PET/CT
16%
Malignant Disease
16%
Volume-of-interest
16%
Clinical Targets
16%
Receptor Targets
16%
Safe Use
16%
In Cancer
16%
Renal Excretion
16%
Adverse Events
16%
Metastasis
16%
Intravenous Dose
16%
PET Image
16%
Cancer 2
16%
Diagnostic Strategy
16%
Primary Tumor
16%
Tumor Uptake
16%
Cancer Therapeutic Strategy
16%
Target Dose
16%
Patients with Breast Cancer
16%
Targeting Peptide
16%
Pharmacologic Effects
16%
Effective Dose
16%
Safety Assessment
16%
Tissue Compartments
16%
Aggressiveness
16%
Vital Signs
16%
Cancer Patients
16%
Clinical Potential
16%
PET Scan
16%
Cancer Diagnostics
16%
Radiation Burden
16%
Overexpression
16%
Malignant Tissue
16%
Medicine and Dentistry
Dosimetry
100%
Neoplasm
100%
Urokinase Receptor
100%
positron emission tomographic scan
100%
Gallium 68
100%
Human Study
100%
Radioligand
100%
Bladder Cancer
50%
Prostate Cancer
50%
Breast Cancer
50%
Biodistribution
33%
Clinical Trial
33%
Malignant Neoplasm
33%
Positron Emission Tomography-Computed Tomography
16%
Biological Marker
16%
Vital Sign
16%
Polyethylene Terephthalate
16%
Primary Tumor
16%
Whole Body PET
16%
Metastatic Carcinoma
16%
Safety Assessment
16%
Diseases
16%
Blood Screening
16%
Adverse Event
16%
Intravenous Drug Administration
16%
Diagnosis
16%
Screening Test
16%
Urinary Excretion
16%
Pharmacology, Toxicology and Pharmaceutical Science
Gallium 68
100%
Radioligand
100%
Neoplasm
100%
Human Study
100%
Urokinase Receptor
100%
Polyethylene Terephthalate
100%
Dosimetry
100%
Bladder Cancer
50%
Prostate Cancer
50%
Breast Cancer
50%
Biodistribution
33%
Malignant Neoplasm
33%
Clinical Trial
33%
Diseases
16%
Renal Excretion
16%
Safety Assessment
16%
Adverse Event
16%
Primary Tumor
16%
Biological Marker
16%